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Using SELEX (systematic evolution of ligands by exponential enrichment), we serendipitously discovered a ssDNA aptamer that
binds selectively to the anti-FLAG M2 antibody. The aptamer consisted of two motifs (CCTTA and TGTCTWCC) separated by
2-3 bases, and the elimination of one or the other motif abrogated binding. The DNA aptamer and FLAG peptide competed
for binding to the antigen-binding pocket of the M2 antibody. In addition, the aptamer eluted FLAG-tagged proteins from the
antibody, suggesting a commercial application in protein puriﬁcation. These ﬁndings demonstrate the feasibility of using SELEX
to develop ssDNA aptamers that block the function of a speciﬁc antibody, a capability that could lead to the development of novel
therapeutic modalities for patients with systemic lupus erythematosus, rheumatoid arthritis, and other autoimmunediseases.
1.Introduction
Antinuclear antibodies are diagnostic markers of systemic
lupus erythematosus, rheumatoid arthritis, and other auto-
immune diseases [1]. In these B lymphocyte disorders, a
large variety of autoantibodies are made against nuclear self-
antigens, including ribonucleoproteins, nucleosomes, chro-
matin, and polynucleotides (RNA, ssDNA, and dsDNA).
Among these, anti-DNA antibodies have been the most ex-
tensively studied [2]. Anti-DNA antibodies bind with high-
aﬃnity to either single- or double-stranded DNA and many
tend to favor association with pyrimidine bases [3, 4]. Sev-
eral reports have also described antinuclear antibodies cross-
reacting with peptide self-antigens and depositing in the
brain, kidneys, and skin [5–9]. As proposed by several inves-
tigators, this deposition may be a cause of inﬂammation-
mediated tissue damage, especially in the kidneys where
n e p h r i t i si sam a j o rs o u r c eo fm o r b i d i t y[ 1, 2]. In mouse
models of systemic lupus erythematosus, attempts were
made toblockthe functionofthese cross-reacting antibodies
using peptide aptamers, derived either from their cognate
peptide self-antigens orfrom phage display libraries [10, 11].
In some cases, the peptide aptamer competitively associat-
ed with the antinuclear autoantibodies, thereby preventing
antibody-mediated tissue damage [10, 11]. Thus, direct anti-
bodyinhibitionmightbeaneﬀectivetherapyinpatientswith
autoimmune diseases driven by the presence of antinuclear
antibodies. Anotherviable approach to blockantinuclearan-
tibodies might be to use DNA aptamers, given the high-
aﬃnity of these antibodies for DNA and evidence of nucle-
otide base speciﬁcity. But this approach has clearly been un-
derexplored, perhaps due to the lack of reports on the fea-
sibility of developingDNAaptamers to block the function of
speciﬁc antibodies.
An adaptive technique employed to deﬁne the sequence
speciﬁcity of DNA/RNA-binding proteins is SELEX (sys-
tematic evolution of ligands by exponential enrichment). In
SELEX, the protein of interest is used as a selection matrix
to capture high-aﬃnity DNA binding sites from a pool of
randomized DNAmolecules[12, 13].This pool is comprised
of an oligonucleotide that contains a randomized core (up
to 35 bases in size) ﬂanked by PCR priming sequences.2 Journal of Nucleic Acids
The randomized core is made during chemical synthesis us-
ing a mixture of all four nucleoside phosphoramidites at
each of the random positions. Following their capture, the
selected DNA molecules are reampliﬁed by PCR and then
further enriched through successive rounds of selection.
After4–6rounds,theselectedDNAmoleculesareclonedand
sequenced to identify any common DNA motifs recognized
by the protein of interest. SELEX can be applied to the se-
lection of ssDNA, dsDNA, or even RNA molecules [12, 13].
It is a powerful tool that has been used to optimize nucleic
acid ligands for a multitude of proteins, even some which
do not normally interact with DNA or RNA. As an example,
SELEX was utilized to develop RNA aptamers that bind
to blood coagulation factors, including thrombin [14], Von
Willebrandfactor[15],andFactorIXa[16].Inallthreecases,
the selected RNA aptamers interacted selectively with their
corresponding protein targets and, in the process, inhibited
their blood coagulation activities. A second generation of
aptamers was developed, and, among these, some have
entered clinical trials in patients with blood coagulation dis-
orders [15].
Using SELEX, we serendipitously discovered a ssDNA
sequence that binds selectively to the M2 antibody, a
commonly used reagent that recognizes the Flag epitope
(DYKDDDDK). The DNA aptamer and Flag peptide com-
peted for binding to the M2 antibody, thereby allowing the
aptamer to elute Flag-tagged proteins from an immobilized
M2 antibody, a commonly employed procedure in protein
puriﬁcation. Aside from this immediate application in pro-
teinpuriﬁcation,identiﬁcationofthisDNAaptamerdemon-
strates the feasibility of using SELEX to develop aptamers
that block speciﬁc antibodies. Applying this approach to
antinuclear autoantibodies could lead to the development of
novel therapeutic strategies for patients with systemic lupus
erythematosus,rheumatoidarthritis, andotherautoimmune
diseases.
2.Materialsand Methods
2.1. Materials. Oligonucleotides were synthesized by the
EppleyCore Facility (University ofNebraskaMedical Center,
Omaha, NE). Plasmid pTetFLAGhTRF245−501 was a gift
from Dr. Titia de Lange (Rockefeller University, New York,
NY) [17]. The polynucleotide kinase and the Platinum Pfx
and Taq DNA polymerases were purchased from Invitrogen
(Carlsbad, CA). All other enzymes were obtained from
Fermentas (Hanover, MD), New England BioLabs (Beverly,
MA),Promega(Madison,WI),orInvitrogen(Carlsbad,CA).
The TnT Quick coupled Transcription/Translation System
was purchased from Promega (Madison, WI). The γ-[
32P]-
ATP (4500Ci/mmol) was purchased from MP Biologicals
(Solon, OH), and the L-[35S]-Methionine (1000Ci/mmol)
was obtained from PerkinElmer (Boston, MA). M-450
magneticbeadscoatedwithasheepanti-mouseIgGantibody
were received from Dynal Biotech, Inc., (Lake Success, NY).
3XFLAG peptide and all other chemicals were from Sigma-
Aldrich (St. Louis, MO). The Mini-PROTEAN 4%–20%
SDS-PAGE gels were purchased from Bio-Rad (Hercules,
CA).
2.2. Antibodies. Mouse monoclonal antibodies against the
Flag tag (IgG1 clone M2) and StnI/OBFC1 (IgG2ak clone
3G12-1B7) were purchased from Sigma-Aldrich (St. Louis,
MO). Normal mouse IgG (cat. # sc-2025) and anti-vimentin
mouse monoclonal antibody (IgG1 clone sc-6260) were ob-
tained from Santa Cruz (Santa Cruz, CA), as was the rab-
bit polyclonal antibody against TRF2 (cat. # H-300). Also
purchased were mouse monoclonal antibodies against PTOP
(IgG1 clone 1D8-1B6; Novus Biologicals, Littleton, CO) and
TIN2 (IgG1 clone 59B388, AbCam, Cambridge, MA).
2.3. Expression Vectors. The plasmid pcDNA3.1-Flag-Stn1
was made by insertion of the human Stn1 sequences into
plasmid pcDNA3.1-Flag. The coding sequence of Stn1 was
ampliﬁedfromplasmidpOTB7-Stn1(GenBank#BC017400;
American Type Culture Collection, Manassas, VA) using
the Platinum Pfx DNA polymerase and primers 5 -GA-
CTGACAATTGGGTGGTATGCAGCCTGGATCCAG-CC-
3  and 5 -GACTGAAGATCTTCAGAACGCTGTGTAGTA-
GTG-3 . The PCR product was then cut with MfeI/BglII and
inserted into the EcoRI/BamHI sites of pcDNA3.1-Flag, in
frame with the Flag tag. pcDNA3.1-Flag is a pcDNA3.1(−)
vector encoding a Flag epitope located downstream of
a T7 promoter and immediately followed by an EcoRI
site. Plasmid pcDNA3.1-Flag-TRF2ΔB was made from its
pCMV1 equivalents by transfer of its TRF2 cassette to
vector pcDNA3.1(−) (Invitrogen, Carlsbad, CA). pCMV1-
Flag-TRF2ΔB was inturnmadebythetransfer topCMV1ofa
SacII/BamHI fragment from plasmid pTetFLAGhTRF245−501
(a gift from Titia de Lange, RockefellerUniversity, NY) [17].
2.4. Protein Expression. The Flag-Stn1 and [35S]-Flag-
TRF2ΔB proteins were made by in vitro transcription/trans-
lation in a rabbit reticulocyte lysate. In a ﬁnal volume of
50μL, one microgram of pcDNA3.1-Flag-Stn1 was tran-
scribed/translated using the TnT Quick Coupled system,
according to the manufacturer’s instructions (Promega,
Madison, WI). A water-programmed lysate (mock) was pro-
duced in parallel to serve as a negative control. After transla-
tion, aliquots of the two reactions were analyzed by western
blotting using both the Stn1/OBFC1 antibody and anti-Flag
M2 antibody. A single species of 45kDa was detected by
the two antibodies in the Stn1-programmed lysate but not
the Mock lysate (See Figure S1 in Supplementary Material
available online at doi: 10.4061/2011/720798). The [35S]-
labeled Flag-TRF2ΔB proteinwas producedsimilarly with the
exception that the unlabeled methionine was replaced with
2μLo fL - [ 35S]-methionine (1000 Ci/mmol, 10μCi/μL).
2.5. Preparation of Beads Coated with the Anti-Flag M2 Anti-
body. M2 antibody-coated beads were prepared by mixing
200μL of M-450 magnetic beads coated with a sheep anti-
mouse IgG antibody (Dynal Biotech, Inc., Lake Success, NY)
with 15μg of anti-Flag antibody (M2 mouse monoclonal,
Stratagene, La Jolla, CA) in 5mL of PBS containing 0.1%
each ofNP-40 and BSA.After overnight rotationat 4◦C, M2-
coated beads were washed 3 times in PBS containing 0.1%
each of NP-40 and BSA, after which beads were suspended
a n ds t o r e di n2 0 0 μLo ft h es a m eb u ﬀer. Before use, beadsJournal of Nucleic Acids 3
were washed 3 times with ice-cold 1X binding buﬀer con-
taining 0.1% BSA. Control beads coated with normal mouse
IgG (cat. # sc-2025, Santa Cruz) were prepared following the
same exact protocol.
2.6. SELEX. An oligonucleotide containing a random core
of 35 nucleotides ﬂanked by PCR priming sequences was
made: 5 -GCGTCGACAAGCTTTCTAGA(N)35GAATTC-
GGATCCCTCGAGCG-3 . In the ﬁrst round of selection,
5μg of this randomized oligo (215 pmoles, 130 trillion mol-
ecules) was incubated with 12.5μL of rabbit reticulocyte ly-
sate(programmedwitheitherwaterorFlag-Stn1)and5μgof
sonicated denatured E. coligenomic DNAin a 50μLr e a c t i o n
containing 1X binding buﬀer (4% glycerol, 1mM MgCl2,
1mM DTT, 50 mM NaCl, 10mM Tris-HCl pH 7.5). After
30 minutes at room temperature, 10μL of M2-coated beads
were added and the samples were rotated at room tempera-
turefor1hour.Magneticbeadswerewashed3timeswithice-
cold 1X binding buﬀer containing 0.1% BSA, after which the
selected oligos were eluted for 10 minutes at room tempera-
ture in the presence of an excess of 3XFLAG peptide (34μM
in 1X binding buﬀer). Next, the eluted DNA was reampliﬁed
by PCR using Platinum Taq DNA polymerase and primers
5 -GCGTCGACAAGCTTTCTAGA-3  (forward) and 5 -
CGCTCGAGGGATCCGAATTC-3  (reverse). Aliquots taken
after 10, 15, 20, and 25 cycles of PCR were resolved on a 3%
agarose gel. The most optimally ampliﬁed aliquot (no smear,
no supershift, within the exponential range) was select-
ed, cut, and gel puriﬁed using the GENECLEAN III kit (MP
Biologicals,Solon,OH).Next,thegel-puriﬁedproductswere
subjected to asymmetric PCR to regenerate ssDNA mole-
cules needed for the following rounds of SELEX. Sixteen cy-
cles of asymmetric PCR were performed using Platinum
Taq DNA polymerase and the forward primer, after which
the PCR products were extracted with phenol:chloroform
(1:1), chloroform only, and then ethanol precipitated. The
ssDNA pellet was dissolved in water and was ready to be
usedinthenextroundofSELEX.AdditionalroundofSELEX
were done identically, except that the randomized oligo was
replacedwiththepreviouslyselectedandreampliﬁedssDNA.
After the sixth round of selection, the symmetrically
ampliﬁed PCR product was gel puriﬁed and then prepared
for TA-cloning into vector pCR2.1-Topo (Invitrogen, Carls-
bad, CA). Chemically transformed TOP10 E. coli cells were
spread onto plates containing kanamycin (25μg/mL). A total
of 50 white colonies were picked and sent for sequencing.
Over 30 sequences were obtained for each of the two SELEX
procedures performed (mock versus Flag-Stn1).
2.7. Radiolabeling of DNA Probes. In 20μL of forward reac-
tion buﬀer (10mM MgCl2,5 m MD T T ,a n d7 0 m MT r i s -
HCl, pH 7.6), 30pmoles of oligonucleotide were labeled for
15 minutes at 37◦Cw i t h7 5 μCi of γ-[
32P]-ATP (4500Ci/
mmole) and 10 units of T4 polynucleotide kinase (Invit-
rogen, Carlsbad, CA). Next, the probes were resolved by
electrophoresis on an 8% polyacrylamide gel and were gel
puriﬁed. Lastly, the eluted probes were desalted on a G50
spun column (GE Healthcare, Piscataway, NJ).
2.8. Electrophoretic Mobility Shift Assay (EMSA). In 25μL
of 1X binding buﬀer, reactions contained 1μgo ft h ei n d i -
cated antibody and 80,000cpm of the designated [32P]-la-
beled oligonucleotide. Reactions were incubated at room
temperature for 30 minutes, and were then loaded onto a
4% native polyacrylamide gelcontaining TBE buﬀer(45mM
Tris-borate, 2mM EDTA, pH8.3). Gels were runat 4◦Cf o r1
hourat180Volts.Gelswere thentransferred toaDE81anion
exchange chromatography paper (Whatman Internation-
al, Maidstone, England), dried, and exposed to a Phospho-
rImager screen (Molecular Dynamics, Sunnyvale, CA). In
competition experiments, the indicated competitors were
added 5 minutes prior to the addition of the [32P]-labeled
ABA probe. The competitors used included an increasing
concentration of 3XFLAG peptide (2, 5, 10, 20, 50, 100, 200,
o r5 0 0 n M )o ra ne x c e s so fe i t h e rt h eA B Ao rC T Ro l i g o
(500nM each).
2.9. Binding Isotherm of the ABA Probe. Experiments were
performed with [32P]-labeled ABA as described above, ex-
ceptthattheM2antibodywasaddedatanincreasingconcen-
tration (0, 50, 100, 200, 350, 500, 750, 1000, 2000, and
4000ng). After exposure of the gel to a PhosphorImager
screen, the amount of free [32P]-ABA and amount of [32P]-
ABA bound to the M2 antibody were quantiﬁed by volume
integration using ImageQuant program (Molecular Dynam-
ics, Sunnyvale, CA). The amount of [32P]-ABA bound,
expressed as a fraction of the total, was plotted as a function
of total amount of M2 antibody. The resulting curves were
ﬁttedbynonlinear regression toa “one-site”saturation bind-
ing curve ([ 32P]-ABA bound = [M2]/(KD +[M2])). Fitting,
performed using SigmaPlot version 11.0, allowed calculation
of the apparent dissociation constant (KD).
2.10. Release of the Captured [32P]-ABA Oligo by the 3XFLAG
Peptide. The [32P]-labeled ABA oligo was ﬁrst immobilized
onto the M2-coated beads. Brieﬂy, 150μLo fM 2 - c o a t e d
beads were added to 375μLo f1 Xb i n d i n gb u ﬀer containing
600,000cpm of [32P]-ABA oligo. Capture of the oligo was
allowed to proceed for one hour at room temperature, after
which the beads were washed 3 times with 500μLo fi c e - c o l d
1X binding buﬀer (containing 0.1% BSA). The radioactive
beads were thenresuspended in450μLo fth es a m ebuﬀer.To
assess theabilityofthe3XFLAGpeptidetoelutethecaptured
oligo, an increasing concentration of 3XFLAG peptide (0,
2, 5, 10, 20, 50, 100, 200, 500, 1000, 2000, and 5000nM)
was added to 30μLo fb e a d sc a r r y i n gt h e[ 32P]-ABA oligo.
After 20 minutes at room temperature, the beadswere pulled
down and the amounts of radioactivity remaining on the
beads and in the supernatant were counted by scintillation
and expressed as a fraction of the total.
2.11. Inhibition of the Capture of [35S]-Labeled Flag-TRF2ΔB.
Prior to these experiments, beads were blocked at 4◦Cf o r
30 minutes with 5% milk in 1X binding buﬀer to reduce
nonspeciﬁc binding. In 1X binding buﬀer, M2-coated beads
were ﬁrst incubated with the indicated competitor (30μM
e a c h3 X F L A G ,3 X A B A ,o r3 X C T R )o rw i t hn oc o m p e t i t o r
(No Comp). After 10 minutes at room temperature, 2–10μL4 Journal of Nucleic Acids
of [35S]-labeled FLAG-TRF2ΔB were added. After 1 hour of
rotation at room temperature, each reaction was washed 3
times with 500μL of ice-cold 1X binding buﬀer (containing
0.1% BSA), after which the amount of [35S]-Flag-TRF2ΔB
captured was quantiﬁed. In one experiment, the amount
captured was quantiﬁed by SDS-PAGE electrophoresis and
exposure to a PhosphorImager screen. In a second experi-
ment done in triplicate, the amount of [35S]-Flag-TRF2ΔB
captured was quantiﬁed by scintillation counting. In both
experiments, beads coated with normal mouse IgG were
included as a negative control for the capture (IgG).
2.12. Release of Precaptured [35S]-Labeled Flag-TRF2ΔB. The
[35S]-labeled Flag-TRF2ΔB protein was ﬁrst immobilized
onto the M2-coated beads. Brieﬂy, 80μL of M2-coated beads
were added to 800μLo f1 Xb i n d i n gb u ﬀer containing 32μL
of [35S]-Flag-TRF2ΔB. Capture of the protein was allowed
to proceed for one hour at room temperature, after which
the beads were washed 3 times with 500μL of ice-cold 1X
bindingbuﬀer(containing0.1%BSA).Theradioactive beads
were then resuspended in 80μLo ft h es a m eb u ﬀer. To assess
the ability of the 3XABA oligo to elute the captured protein,
ﬁve microliters of these beads were mixed with 45μLo f1 X
binding buﬀer containing the indicated competitor (30μM
e a c h3 X F L A G ,3 X A B A ,o r3 X C T R )o rn oc o m p e t i t o r( N o
Comp). After 20 minutes at room temperature, the beads
were pulled down and the amount of radioactivity in the
supernatants was quantiﬁed by SDS-PAGE electrophoresis
and exposure to a PhosphorImager screen. In an experi-
ment done in triplicate, the amount of [35S]-Flag-TRF2ΔB
releasedwasalsoquantiﬁedbyscintillationcounting.Inboth
experiments, beadsboiled to release all of the captured[35S]-
labeled protein were included as positive control for the
elution (Total).
3.Results
3.1. SELEX Driven by the Anti-Flag M2 Antibody. SELEX
was used to characterize the DNA-binding speciﬁcity of
a human Flag-tagged Stn1 protein [18, 19], in this case
produced by in vitro translation in a rabbit reticulocyte cell-
free system. The in vitro translated Flag-Stn1 was mixed
with a pool of randomized ssDNA molecules and then,
the anti-Flag M2 antibody was used to immunoprecipitate
the Flag-Stn1/DNA complexes to select for high-aﬃnity
targets. After six successive rounds of selection, the selected
ssDNA molecules were cloned and sequenced. Analysis of
a related unselected random pool revealed a slight bias
for G-rich sequences, but no evidence of any recurrent
motifs [20]. In contrast, analysis of the Flag-Stn1 selected
oligonucleotides revealed a bipartite consensus motif made
of two distinct elements: CCTTA and TGTCTWCC (where
W = A/T; Figure 1(a)). These elements were separated by
2-3 bases of poorly conserved sequences. However, the
same bipartite consensus motif was also produced when
SELEX was performed with the same antibody but using a
mock-programmed reticulocyte lysate as a control source of
proteins (Figure 1(b)). Based on these results, we concluded
that the bipartite consensus had been selected, not by the
Flag-Stn1 protein, but by the M2 antibody itself or proteins
of the lysate that the antibody cross-reacted with.
3.2. The M2 Antibody Binds the Consensus ssDNA Motifs.
To test the possibility of direct interactions between the
bipartite consensus and M2 antibody, EMSAwas performed.
As e r i e so fe q u a ll e n g t h[ 32P]-labeled ssDNA probes con-
taining or lacking each element of the consensus were made
(Figure 2(a)). Probes AB, BA, and ABA carried both the
CCTTA and TGTCTWCC motifs, whereas probe 2XB and
4XAconsistedofmultiplecopiesofone ortheotherelement.
The unrelated CTR probe was used as negative control.
Figure 2(b) shows that the M2 antibody could form a stable
complex with the ABA probe and to a lesser extent, the AB
probe. None of the other probes interacted with the M2
antibody. Also noteworthy, neither the BA probe lacking the
CCTTA element nor the AA probe lacking the TGTCTWCC
element interacted with the antibody, thereby indicating that
both elements are essential for binding. Figure 2(b) also
shows that among 7 diﬀerent antibodies, the M2 antibody
only interacted with probe ABA. These results show that
probe ABAbinds veryselectively to theM2 antibody, thereby
suggesting that these interactions are involving the variable
regionsoftheantibody,whetherpartofthelightchain,heavy
chain, or both.
To measure the aﬃnity of the M2 antibody for probe
ABA,theapparentdissociationconstant(KD)ofthec om ple x
wasdetermined.AbindingisothermwasgeneratedbyEMSA
using a constant amount of [32P]-ABA incubated with
an increasing concentration of M2 antibody (Figure 2(c)).
Plotting the amount of ABA bound as a function of the total
concentration of antibody generated a binding isotherm.
Fitting of this isotherm to a “one site” saturation binding
curve allowed for calculation of the KD.I nt h i sc a s e ,t h e
apparent KD was determined to have a value of 80 ± 7nM
(Figure 2(d)). The value is comparable to the apparent KD of
otherpreviouslyreportedDNAaptamer/antibodycomplexes
[21]. This result shows that the M2 antibody binds with high
aﬃnity to its preferred DNA ligand, the ABA probe.
3.3. The Flag Peptide Competes with the Binding of the ABA
Oligo to the M2 Antibody. The M2 antibody binds to both
the Flag peptide (DYKDDDDK) and the ABA probe, so we
sought to determine whether the two ligands could compete
for each other. In a ﬁrst series of experiments, we asked
if an excess of 3XFLAG peptide (MDYKDHDGDYKDH-
DIDYKDDDDK) could block the binding of [32P]-labeled
ABA to the M2 antibody. In the EMSA shown in Figure 3(a),
an increasing concentration of 3XFLAG peptide was incu-
bated with the M2 antibody prior to adding the [32P]-
ABA. At concentrations of 50nM and higher, the 3XFLAG
peptidecouldcompletelyblockthebindingofABAtotheM2
antibody. A similar inhibition was produced following the
inclusion of an excess of unlabeled ABA oligo, but not after
the addition of the CTR oligo. These results show that the
3XFLAGpeptide competeswith thebinding of probeABAto
the M2 antibody.
In a second series of experiments, we asked whether an
excess of 3XFLAG peptide could elute a [32P]-ABA oligoJournal of Nucleic Acids 5
ACGGGGATCCGATAATCTCCCTTTCCAAACCTTAT
GTGAGGAGCGATCCGTTGTACCTTAAT TGTCTTCC
CTCTAGAGGGGTTCGTTGTCCTTAATTGCTCTACC
AGCGTAGAGGGTATGTCAACCTTATTATGTCTTYK
TCGCGGGTTCCGACATATACCTTAAACTGACTACC
GCTCTGGGATTCGTGTAGCCTTAGA TGTCTTCCTT
CGAGGGCCGAAGAGCGTCCTTAAT AGTCTACCTTG
GGGGCCCGTGATGTAGCCTTAATCTGTCTTCCTTG
GGGACGATTTCTGCATCCTTAGC TGTCTTCCAGTG
TGGGGTCTGGGTTCGCCCTTAGA TGTCTTCCTCAC
KGGGGRCCGCTTTCACCCTTAMC TGTCTTCYGTTY
GGTGATCGAAGTTTTCCTTAATCTGTCTACCGTAT
GGCTCGGGGGGTTTCCTTAAT TGTCTACCGCATCC
GGGTTACGCTCTSCCTTAGT TGTCTTCCGCTTTAT
CCTTAATTTATCTACCTCAGGGAAAGCGTATGACG
CCTTAGT TGTCTTCCTGTACGGCAGAGGAGGCGTG
Consensus: CCTTANNNTGTCTWCC
–
–
–
–
–
–
–
–
–
(a)
GCCCTAACTACCTTTCATGACCTTAGAAGGGCCTA
GTAGGTATATTCTTCCTTATGGGCGTGGAGACACT
TTTCCTGGCCTTACTGAGCGCGTTCGACCCATATA
CACACACCTTATTGAGACTACCATGTGGGGCTAGT
AGCGACTTCTACCAAGCTTTTCCTTAT TGTCGCT
GGTCGTGGGAACGTTTAACCCTTAATTGCTCTACC
CTCGAGTGGTCCACGCATACTTATC TGTCTACCTG
CGAGGGGTTGATATTCTCCTTATTTTGACTACCCA
GGGGACGGCATTTGTACCTTAGA TGTCTTCCTACT
TGGGGTCTGGGTTCGCCCTTAGA TGTCTTCCTCAC
CCGAGGGGTACGTTCGCCTTAAT TGTTCTTCCTAT
GGGGTCCGAGCACAGTCCTTATTTACTCTACCATG
TCCTAATTATAGTTTTCCTTATTGAGTCTACCTGT
GGGGGCGAATTTATTCCTTAGT TGTCTTCCGTTTA
GGGGCGGATCGTCATCCTTAGGCTATCTACCGTAC
GGGGTGCGATCATCTCCTTATATTGTCTACCATTT
GGGTCCATCTGATTCCTTAGGCTGTCTTCCTCTTA
GGGGTCCGTTGTGTCCTTAGTTACTCTACCATACT
TGACCGTGCCCTTAAT TGTCTACCAGCTGGTCATA
GCCTCTTCCTTTC TGTTCATTATGCTCTGCGCGTC
TTCCTTAGTAGTTTCTACCTAGCGCATGTCGGCAG
CCTTATTTTTGACTACATTTTAGAGCTTCGACGTA
CCTTAAT TGTTCTACCACTTGAGCGCTTGGCACGT
CCTTTATTTATCTACCTGGGGCGGGCGACCTGTAT
Consensus: CCTTANNNTGTCTWCC
––
–
–
–
–
–
–
–
–
–
(b)
Figure 1: SELEX with or without the Flag-Stn1 protein yields the same bipartite consensus. A randomized pool of ssDNA molecules was
incubated with an in vitro translation system programmed with either a Flag-Stn1 plasmid (Flag-Stn1 present) or water (Flag-Stn1 absent),
after which protein/DNA complexes were recovered by immunoprecipitation using the anti-Flag M2 antibody. After six successive rounds of
selection, the remaining oligonucleotides were cloned and sequenced. (a) Oligonucleotides selected in the presence of the Flag-Stn1 protein.
The selected ssDNA molecules share a common bipartite consensus, which consists of a CCTTA (pink) and TGTCTWCC (green) motifs.
Nonnucleotide letters denote ambiguous sequencing reads (R = A/G, Y = C/T, S = C/G, W = A/T, K = T/G, M = A/C). (b) Oligonucleotides
selected in the absence of the Flag-Stn1 protein. The same bipartite consensus is shared among the ssDNA molecules selected by the mock-
programmed in vitro translationsystem.6 Journal of Nucleic Acids
CTR TCGATAGATGTAGTGCACAGATGGTGTGAG
2XB TCGATGTCTTCCGGCAGTGTCTTCCGTGAG
4XA TTTCCTTATTCCTTATTCCTTATTCCTTAG
AA TCGATTTCCTTAATGCACTTCCTTAGTGAG
AB TCGATTTCCTTAGTTGTCTTCCGGTGTGAG
BA TCGATAGATGTAGTTGTCTTCCTTAGTGAG
ABA TCGATTTCCTTAGTTGTCTTCCTTAGTGAG
AB A
3XCTR TCGATAGATGTAGTGCACAGATGGTGTGCACAGATGGTGTGCACAGATGGTGTGAG
3XABA TCGATTTCCTTAGTTGTCTTCCTTAGTTGTCTTCCTTAGTTGTCTTCCTTAGTGAG
AB AB AB A
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Figure 2: The bipartite ssDNA consensus binds directly to the anti-Flag M2 antibody. (a) Sequence and graphical representation of the
probes used. Allprobes were labeled atthe5 -end with [32P].Probes were designed to carry none,one,orboth ofthe identiﬁed motifs.Motif
A = CCTTA (pink). Motif B = TGTCTWCC (green). (b) The anti-Flag M2 antibody binds selectively to probe ABA. The indicated probes
(80,000cpm) were incubated with the listed antibodies (1μg), after which protein/DNA complexes were resolved by electrophoresis in a
nativepolyacrylamidegel.(c)TitrationoftheM2antibody.AconstantamountofprobeABAwasincubatedwithanincreasingconcentration
of M2 antibody, and the protein/DNA complexes were resolved by native electrophoresis. At the higher antibody concentrations, a larger
protein/DNA complexisobserved(toparrow),whichmayrepresent theproduct ofantibody oligomerization.(d) Bindingisothermofprobe
ABA interacting with the anti-Flag M2 antibody. The scatter plot shows the amount of ABA bound (amount present in both protein/DNA
complexes) as a function of antibody concentration. Dotted line shows ﬁtting of the data to a “one site” saturation binding curve. Nonlinear
regression ofthe data allowed for the determinationof the dissociationconstant(KD = 80 ± 7nM).Error onthe value ofthe KD represents
the 95% conﬁdence interval of the best-ﬁt curve.Journal of Nucleic Acids 7
already bound to the M2 antibody. For this purpose, [32P]-
ABA was ﬁrst captured by magnetic beads coated with the
M2 antibody, after which an increasing concentration of
3XFLAG peptide was added. In Figure 3(b), the amount of
ABA bound to the beads and the amount released from the
beads were plotted as a function of the concentration of the
3XFLAG peptide. The data show that the ABA oligo was very
eﬃciently released by the addition of the 3XFLAG peptide.
A small fraction of oligo, representing 36%, could not be
displaced, but the other fraction was almost completely
released by 2000nM of 3XFLAG peptide. Fitting the data to
a “one site” competition curve allowed for the calculation of
an IC50. In agreement with the values of the KD,t h eI C 50
was determined to be 96nM (95% conﬁdence interval: 72–
127nM). These results show that the 3XFLAG peptide can
elute the ABA oligo when bound to the M2 antibody.
3.4. The 3XABA Oligo Blocks the Association of Flag-Tagged
Proteins with the M2 Antibody. If the ABA oligo and the
Flag peptide compete for binding to the M2 antibody, then
an excess of ABA oligo could potentially allow the elu-
tion of Flag-tagged proteins from the M2-coated beads, a
commonly used procedure in protein puriﬁcation. To ad-
dressthispossibility,weﬁrstdeterminedwhetheranexcessof
ABA oligo could block binding of [S35]-labeled Flag-TRF2ΔB
to M2-coated beads. In these experiments, the M2-coated
beads were ﬁrst incubated with the competitors (30μMo f
3XFLAG peptide, 3XABAor 3XCTR oligos) or with no com-
petitor(NoComp).Then,the[S35]-labeledFlag-TRF2ΔB was
added and the amount of [S35] captured by the beads was
measured by either SDS-PAGE electrophoresis (Figure 4(a))
or scintillation counting (Figure 4(b)). As Figures 4(a)–4(b)
show, the 3XFLAG peptide abolished the capture of the
[S35]-labeled protein whereas the 3XCTRoligo had no eﬀect.
A l t h o u g hn o ta sa c t i v ea st h e3 X F L A Gp e p t i d e ,t h e3 X A B A
oligo inhibited the capture of Flag-TRF2ΔB by 62%. The
shorter ABA aptamer was also tested but found to be less
active (Figure S2), with ABA blocking the capture by 45%
only.
Next, we asked whether an excess of 3XABA oligo could
elute an [S35]-labeled Flag-TRF2ΔB protein already bound to
the M2-coated beads. In these experiments, the [S35]-labeled
protein was ﬁrst captured by the M2-coated beads. Next, the
radioactive beads were exposed to the competitors (30μMo f
3XFLAG peptide, 3XABA or 3XCTR oligos) or to no com-
petitor (No Comp), and the amount of [S35] released was
quantiﬁed by either SDS-PAGE electrophoresis (Figure 4(c))
or scintillation counting (Figure 4(d)). As Figures 4(c)-4(d)
show, the 3XFLAG peptide caused the release of 54% of the
captured protein whereas the 3XCTR oligo had no activity.
The 3XABA oligo was almost as eﬀective as the 3XFLAG
peptide, causing the release of 36% of the bound protein.
4.Discussion
The initial intent of this study was to use SELEX to char-
acterize the ssDNA-binding speciﬁcity of Flag-tagged Stn1,
a subunit of the CST complex [18, 19]. Instead, the SELEX
procedureenriched forssDNAmoleculesthatbindwith high
aﬃnity to the anti-Flag M2 antibody. How was this selection
bytheantibodyevenpossible?First,itmaybethatthein vitro
translated Flag-Stn1 protein did not possess the minimum
required DNA-bindingactivity. Improper folding could have
contributed to this lack of activity. Alternatively, it may be
that the OB-fold domain (oligonucleotide/oligosaccharide
binding) of Stn1 is involved in mediating protein-protein
interactions rather than DNA-binding [18, 19]. Second, the
Flag epitope (DYKDDDDYK) is highly negatively charged,
making it possible for an optimized DNAmolecule to mimic
the electrostatic signature of the peptide. Third, ssDNA is far
more ﬂexible than dsDNA, and in that respect, could more
readily adapt to the positively charged surface of the antigen-
binding pocket of the M2 antibody [22]. In other words,
we propose that selection mediated by the antibody would
not have been possible if the Flag epitope had been neutral
or positively charged, if SELEX had been performed using
dsDNA, or if the Flag-tagged Stn1 protein had exhibited a
higher aﬃnity for ssDNA. In fact, we have successfully used
SELEXundersimilarconditionstodeﬁnethessDNAbinding
speciﬁcity of POT1, a protein that recognizes telomeric
DNA. This SELEX, also performed using the M2 antibody,
almost exclusively selected for telomeric sequences with no
evidence of the bipartite motif detected (Choi, K. H. and
Ouellette, M. M., manuscript in preparation). The selection
bySELEXofoﬀ-targetaptamersisnotuncommon,especially
when selecting single-stranded nucleic acids [23]. Oﬀ-target
aptamers that bind to the selection matrix (e.g. avidin, M2
antibody), as we have observed here, have also been reported
by others [23]. Hence, caution and experimental controls
are necessary, especially when selecting ssDNA molecules
for their binding to a protein of unknown functionality.
Under these conditions, an important control to perform,
as we have done here, is a mock selection to verify that the
molecules were indeed selected by the protein of interest.
Our ﬁndings show that the identiﬁed bipartite consensus
binds selectively and with high aﬃnity to the M2 antibody.
An important ﬁnding was the speciﬁcity of this interaction.
For example, the consensus did not bind to any of the other
antibodies tested, many of which belonging to the same
isotype as the M2 antibody (mouse IgG1). This speciﬁcity
implied that the interactions involved the variable regions
of the antibody, which together form the antigen-binding
pocket. This assumption was conﬁrmed by the results of the
competitionexperiments.AsFigure 4shows,thessDNAcon-
sensus could very eﬃciently displace the Flag peptide from
the antigen-binding pocket of the M2 antibody. Converse-
ly,theFlagpeptidecouldsimilarly displacetheDNAaptamer
from the antibody as well (see Figure 3). This competition
between the Flag peptide and DNA aptamer implies that the
two are recognized by overlapping binding determinants at
the surface of the antibody. A shared feature of the Flag pep-
tide and ABA aptamer is their negative electrostatic charges.
On the surface of the antibody, these negative charges on
the two ligands are likely to interact with some of the same
binding determinants. The binding pocket of the M2 anti-
body appears to be speciﬁc only for the ﬁrst 4 amino acids
of the Flag peptide, namely, DYKD [22]. Two clusters of
positively charged residues (lysines, arginine, histidine) are8 Journal of Nucleic Acids
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Figure 3: The 3XFLAG peptide blocks the binding of ABA to the M2 antibody. (a) The 3XFLAG peptide prevents formationof the ABA/M2
complex. The M2 antibody was incubated with an increasingconcentration of3XFLAG peptide after which the [32P]-ABA probe was added.
Protein/DNA complexes were resolved by electrophoresis in a native polyacrylamide gel. (b) The 3XFLAG peptide elutes the ABA probe
already bound to the M2 antibody. The [32P]-ABA was ﬁrst captured by magnetic beads coated with the M2 antibody. The beads were then
incubated with an increasing concentration of 3XFLAG peptide and the amount of [32P]-ABA released and remaining on the beads was
counted by scintillation (n = 1).
present in the binding pocket, each capable of coordinating
an aspartate within the DYKD motif. The same two clusters
could potentially interact with phosphate groups present
within the backbone of the ABA oligo. Also important for
the binding are two tyrosine residues, each one capable of
forming stacking interactions with the tyrosine of DYKD.
When bound to the ABA oligo, the same tyrosines could
providestackinginteractionstosomeofthenucleotidebases.
Yet,theselimitedinteractionswouldnotsuﬃcetoexplainthe
sequence speciﬁcity observed. The selected consensus con-
sisted oftwoseparatemotifs (CCTTAandTGTCTWCC)and
mutating one or the other was suﬃcient to abrogate binding.
To allow recognition of this large bipartite consensus, other
residuesmustbeimplicatedthatmakecontactwithseveralof
the nucleotide bases. Hence, it must be that the Flag peptide
interacts with a subset only of all the residues implicated in
the binding of ABA. If so, then how could the Flag peptide
be so eﬃcient at displacing ABA from the M2 antibody? It is
possible that the binding determinants that the two ligands
share are especially critical for the binding of ABA. A second
possibility would be that the binding of the Flag peptide
causes changes in the conformation of the antibody, and that
these allosteric alterations are incompatible with the binding
ofABA.Howthe ABAaptamer is able tomimic the structure
of the Flag peptide remains to be determined, but this form
of mimicry between peptide and DNA has previously been
reported to play an important role in autoimmune diseases
and may also have important applicationsin drug design [5–
9].The ABAoligoand Flagpeptideoﬀeran idealsystemwith
which to study the structural basis of this form of molecular
mimicry.
One commonly employed procedure in protein puriﬁ-
cation is the capture of Flag-tagged proteins by the M2
antibody and their subsequent release by incubation with
an excess of 3XFLAG peptide [24]. This procedure allows
the elution of the puriﬁed proteins under nondenaturing
conditions. However, the procedure leaves the eluted protein
in solution with an excess of 3XFLAG peptide, which can
pose a problem if the Flag tag needs to remain functional.
A DNA aptamer capable of eluting the Flag-tagged proteins,
such as 3XABA, could alleviate these potential drawbacks.
Once the protein is eluted, the DNA aptamer could conve-
niently be inactivated by an antisense oligo or eliminated us-
ing trace amounts of DNAse. Alternatively, if the aptamer
is biotinylated, its removal could be accomplished using
streptavidin-coated beads. Finally, a DNA aptamer would
also oﬀer the possibility of using mutated oligos as negative
controls or for the diﬀerential elution of captured proteins.Journal of Nucleic Acids 9
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Figure 4: 3XABA oligonucleotide blocks the interaction of Flag-tagged proteins with the M2 antibody. (a)-(b) The 3XABA oligo blocks
the binding of Flag-TRF2ΔB to M2-coated beads. Magnetic beads coated with the M2 antibody were incubated in the absence (No Comp)
or presence of the indicated competitor (3XABA, 3XCTR, 3XFLAG). In vitro translated [35S]-labeled Flag-TRF2ΔB was then added and the
amount captured by the beads was determined by SDS-PAGE electrophoresis and exposure to a PhophorImager cassette (a). In a second
experiment done in triplicate, the amount of [35S]-labeled protein captured was counted by scintillation (b). The amount of [35S]-labeled
protein captured in the absence of competitor (No Comp) was arbitrarily set to 100%. In both experiments, beads coated with normal
mouse IgG were included as negative control for the capture (IgG). Data represent the mean ± S.D. (n = 3). (c)-(d) The 3XABA oligo elutes
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3XFLAG). The amount of [35S]-Flag-TRF2ΔB released was determined by SDS-PAGE electrophoresis and exposure to a PhophorImager
cassette (c). In a second experiment done in triplicate, the amount of [35S]-labeled protein released was counted by scintillation (d). The
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These results described here may also have implications
for the treatment of autoimmune diseases driven by antinu-
clear antibodies. Previous attempts to block the function of
these autoantibodies have been made with peptide mimics,
either isolated from phage display libraries or derived from
peptideself-antigenswithwhich theseantinuclearantibodies
cross-react [10,11].Theseresultsdescribedthereinshowthat
SELEX can be used to identify DNA aptamers that block the
function of a particular antibody. Could this approach be
used to develop aptamers that block the function of anti-
nuclear autoantibodies? In certain autoimmune diseases,
blocking the function of antinuclear autoantibodies has
been shown to limit tissue damage [10, 11]. The sequence
speciﬁcity of antinuclear autoantibodies has not been sys-
tematically investigated [3, 4]. SELEX would represent an
ideal method for characterizing the sequence speciﬁcity of
antinuclear autoantibodies. The SELEX data could serve as
starting point for the design of second-generation aptamers
that might be useful to block the function of these autoan-
tibodies. The development of these DNA aptamers could
therefore represent an alternative approach to the treatment
of patients aﬄicted with systemic lupus erythematosus,
rheumatoid arthritis, and other autoimmune diseases.
5.Conclusion
In summary, SELEX identiﬁed a DNA aptamer that binds
directly to the antigen-binding pocket of the anti-Flag M2
antibody. The DNA aptamer and Flag peptide competed for
binding to the M2 antibody and the aptamer eluted Flag-
tagged proteins from an immobilized M2 antibody. This
new reagent therefore oﬀers an alternative method for the
elution of Flag-tagged proteins bound to the M2 antibody,
a commonly employed procedure in protein puriﬁcation.
Aside from this immediate application in protein puriﬁca-
tion, identiﬁcation of this bipartite consensus demonstrates
the feasibility of using SELEX to develop DNA aptamers
that block speciﬁc antibodies. Applying this approach
to autoantibodies, particularly the antinuclear antibodies,
could lead to the developmentof novel therapeuticstrategies
for patients with systemic lupus erythematosus, rheumatoid
arthritis, and other autoimmune diseases.
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